Ann Haerskjold1,2, Lonny Stokholm3, Marie Linder4, Simon Francis Thomsen5, Gunnar Bergman6, Ingegärd Anveden Berglind4, Helle Kieler4, Henrik Ravn7, Lone Graff Stensballe3. 1. The Child and Adolescent Clinic 4072, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. annhaerskjold@gmail.com. 2. Department of Dermato-Allergology, Herlev and Gentofte Hospitals, University of Copenhagen, Hellerup, Copenhagen, Denmark. annhaerskjold@gmail.com. 3. The Child and Adolescent Clinic 4072, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 4. Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden. 5. Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark. 6. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. 7. Coraxo Consulting, Copenhagen, Denmark.
Abstract
BACKGROUND: Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus. It is prescribed to children at high risk for severe infection with respiratory syncytial virus. However, little is known about the risk of the immune-mediated diseases atopic dermatitis, asthma, and allergic rhinoconjunctivitis after palivizumab exposure. AIM: Our objective was to investigate whether exposure to palivizumab was associated with atopic dermatitis, asthma, or allergic rhinoconjunctivitis in childhood. METHODS: This was a cross-national population-based cohort study including data from 769,523 Danish children born 1 January 1999-31 December 2010 and 581,742 Swedish children born 1 July 2005-31 December 2010. Since palivizumab is only indicated for children at the highest risk, sub-cohorts of preterm children, children with bronchopulmonary dysplasia, and children with hemodynamic significant heart disease were defined. RESULTS: Of the 1,351,265 children included, 1192 (0.09%) were exposed to palivizumab. An increased risk of asthma after palivizumab exposure was observed in the total birth cohort (hazard ratio [HR] 1.49; 95% confidence interval [CI] 1.32-1.68) and in the sub-cohort of preterm children (HR 1.24; 95% CI 1.07-1.44). However, post hoc analyses using the propensity score to balance confounding factors found no increased risk of asthma in preterm children (HR 0.91; 95% CI 0.56-1.48). No increased risks of atopic dermatitis (HR 1.18; 95% CI 0.94-1.48) or allergic rhinoconjunctivitis (HR 1.14; 95% CI 0.92-1.42) were observed. CONCLUSION: Exposure to palivizumab neither increased the risk of atopic disease nor protected against asthma.
BACKGROUND:Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus. It is prescribed to children at high risk for severe infection with respiratory syncytial virus. However, little is known about the risk of the immune-mediated diseases atopic dermatitis, asthma, and allergic rhinoconjunctivitis after palivizumab exposure. AIM: Our objective was to investigate whether exposure to palivizumab was associated with atopic dermatitis, asthma, or allergic rhinoconjunctivitis in childhood. METHODS: This was a cross-national population-based cohort study including data from 769,523 Danish children born 1 January 1999-31 December 2010 and 581,742 Swedish children born 1 July 2005-31 December 2010. Since palivizumab is only indicated for children at the highest risk, sub-cohorts of preterm children, children with bronchopulmonary dysplasia, and children with hemodynamic significant heart disease were defined. RESULTS: Of the 1,351,265 children included, 1192 (0.09%) were exposed to palivizumab. An increased risk of asthma after palivizumab exposure was observed in the total birth cohort (hazard ratio [HR] 1.49; 95% confidence interval [CI] 1.32-1.68) and in the sub-cohort of preterm children (HR 1.24; 95% CI 1.07-1.44). However, post hoc analyses using the propensity score to balance confounding factors found no increased risk of asthma in preterm children (HR 0.91; 95% CI 0.56-1.48). No increased risks of atopic dermatitis (HR 1.18; 95% CI 0.94-1.48) or allergic rhinoconjunctivitis (HR 1.14; 95% CI 0.92-1.42) were observed. CONCLUSION: Exposure to palivizumab neither increased the risk of atopic disease nor protected against asthma.
Authors: Timothy F Feltes; Henry M Sondheimer; Robert M R Tulloh; Brian S Harris; Kathryn M Jensen; Genevieve A Losonsky; M Pamela Griffin Journal: Pediatr Res Date: 2011-08 Impact factor: 3.756
Authors: Ann Haerskjold; Marie Linder; Lonny Henriksen; Simon Francis Thomsen; Helle Kieler; Henrik Ravn; Lone Graff Stensballe Journal: Paediatr Drugs Date: 2016-12 Impact factor: 3.022
Authors: Xavier Sáez-Llorens; María T Moreno; Octavio Ramilo; Pablo J Sánchez; Franklin H Top; Edward M Connor Journal: Pediatr Infect Dis J Date: 2004-08 Impact factor: 2.129
Authors: Shelagh M Szabo; Adrian R Levy; Katherine L Gooch; Pamela Bradt; Hardy Wijaya; Ian Mitchell Journal: Paediatr Respir Rev Date: 2013-01 Impact factor: 2.726
Authors: Steven M Brunwasser; Brittney M Snyder; Amanda J Driscoll; Deshayne B Fell; David A Savitz; Daniel R Feikin; Becky Skidmore; Niranjan Bhat; Louis J Bont; William D Dupont; Pingsheng Wu; Tebeb Gebretsadik; Patrick G Holt; Heather J Zar; Justin R Ortiz; Tina V Hartert Journal: Lancet Respir Med Date: 2020-08 Impact factor: 30.700
Authors: Amanda J Driscoll; S Hasan Arshad; Louis Bont; Steven M Brunwasser; Thomas Cherian; Janet A Englund; Deshayne B Fell; Laura L Hammitt; Tina V Hartert; Bruce L Innis; Ruth A Karron; Gayle E Langley; E Kim Mulholland; Patrick K Munywoki; Harish Nair; Justin R Ortiz; David A Savitz; Nienke M Scheltema; Eric A F Simões; Peter G Smith; Fred Were; Heather J Zar; Daniel R Feikin Journal: Vaccine Date: 2020-01-20 Impact factor: 3.641